Pharmacotherapies for parkinson's disease symptoms related to cholinergic degeneration

Abstract: Dopamine depletion is one of the most important features of Parkinson's Disease (PD). However, insufficient response to dopaminergic replacement therapy suggests the involvement of other neurotransmitter systems in the pathophysiology of PD. Cholinergic degeneration contributes to gai...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Pérez Lloret, Santiago, Peralta, María Cecilia, Barrantes, Francisco José
Formato: Artículo
Lenguaje:Inglés
Publicado: Taylor & Francis 2022
Materias:
TRATAMIENTO MEDICO
ENFERMEDAD DE PARKINSON
NEURODEGENERACION
DETERIORO COGNITIVO
DEMENCIA
Acceso en línea:https://repositorio.uca.edu.ar/handle/123456789/14304
Aporte de:
Repositorio Institucional de la Universidad Católica Argentina (UCA) de Universidad Católica Argentina
id I33-R139-123456789-14304
record_format dspace
institution Universidad Católica Argentina
institution_str I-33
repository_str R-139
collection Repositorio Institucional de la Universidad Católica Argentina (UCA)
language Inglés
topic TRATAMIENTO MEDICO
ENFERMEDAD DE PARKINSON
NEURODEGENERACION
DETERIORO COGNITIVO
DEMENCIA
spellingShingle TRATAMIENTO MEDICO
ENFERMEDAD DE PARKINSON
NEURODEGENERACION
DETERIORO COGNITIVO
DEMENCIA
Pérez Lloret, Santiago
Peralta, María Cecilia
Barrantes, Francisco José
Pharmacotherapies for parkinson's disease symptoms related to cholinergic degeneration
topic_facet TRATAMIENTO MEDICO
ENFERMEDAD DE PARKINSON
NEURODEGENERACION
DETERIORO COGNITIVO
DEMENCIA
description Abstract: Dopamine depletion is one of the most important features of Parkinson's Disease (PD). However, insufficient response to dopaminergic replacement therapy suggests the involvement of other neurotransmitter systems in the pathophysiology of PD. Cholinergic degeneration contributes to gait impairments, cognitive impairment, psychosis, and REM-sleep disturbances, among other symptoms. Areas covered: In this review, we explore the idea that enhancing cholinergic tone by pharmacological or neurosurgical procedures could be a first-line therapeutic strategy for the treatment of symptoms derived from cholinergic degeneration in PD. Expert opinion: Rivastigmine, a drug that increases cholinergic tone by inhibiting the enzyme cholinesterase, is effective for dementia, whereas the use of Donepezil is still in the realm of investigation. Interesting results suggest the efficacy of these drugs in the treatment of gait dysfunction. Evidence on the clinical effects of these drugs for psychosis and REM-sleep disturbances is still weak. Stimulation of the pedunculo-pontine tegmental nuclei (which provide cholinergic innervation to the brain stem and subcortical nuclei) has also been used with some success for the treatment of gait dysfunction. Anticholinergic drugs should be used with caution in PD, as they may aggravate cholinergic symptoms. Notwithstanding, in some patients they might help control parkinsonian motor symptoms.
format Artículo
author Pérez Lloret, Santiago
Peralta, María Cecilia
Barrantes, Francisco José
author_facet Pérez Lloret, Santiago
Peralta, María Cecilia
Barrantes, Francisco José
author_sort Pérez Lloret, Santiago
title Pharmacotherapies for parkinson's disease symptoms related to cholinergic degeneration
title_short Pharmacotherapies for parkinson's disease symptoms related to cholinergic degeneration
title_full Pharmacotherapies for parkinson's disease symptoms related to cholinergic degeneration
title_fullStr Pharmacotherapies for parkinson's disease symptoms related to cholinergic degeneration
title_full_unstemmed Pharmacotherapies for parkinson's disease symptoms related to cholinergic degeneration
title_sort pharmacotherapies for parkinson's disease symptoms related to cholinergic degeneration
publisher Taylor & Francis
publishDate 2022
url https://repositorio.uca.edu.ar/handle/123456789/14304
work_keys_str_mv AT perezlloretsantiago pharmacotherapiesforparkinsonsdiseasesymptomsrelatedtocholinergicdegeneration
AT peraltamariacecilia pharmacotherapiesforparkinsonsdiseasesymptomsrelatedtocholinergicdegeneration
AT barrantesfranciscojose pharmacotherapiesforparkinsonsdiseasesymptomsrelatedtocholinergicdegeneration
bdutipo_str Repositorios
_version_ 1764820523328471043

Ejemplares similares